130 related articles for article (PubMed ID: 1418362)
1. Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
J Geriatr Psychiatry Neurol; 1992; 5(4):192-4. PubMed ID: 1418362
[TBL] [Abstract][Full Text] [Related]
2. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
[TBL] [Abstract][Full Text] [Related]
3. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.
Puri SK; Ho I; Hsu R; Lassman HB
J Clin Pharmacol; 1990 Oct; 30(10):948-55. PubMed ID: 2229455
[TBL] [Abstract][Full Text] [Related]
4. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
6. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
Cutler NR; Murphy MF; Nash RJ; Prior PL; De Luna DM
J Clin Pharmacol; 1990 Jun; 30(6):556-61. PubMed ID: 2355106
[TBL] [Abstract][Full Text] [Related]
7. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
[TBL] [Abstract][Full Text] [Related]
9. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Zemlan FP; Keys M; Richter RW; Strub RL
Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and early clinical studies with velnacrine.
Siegfried KR
Acta Neurol Scand Suppl; 1993; 149():26-8. PubMed ID: 8128834
[TBL] [Abstract][Full Text] [Related]
11. Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.
Wood DM; Ford JM; Roberts CJ
Eur J Clin Pharmacol; 1996; 50(1-2):115-9. PubMed ID: 8739821
[TBL] [Abstract][Full Text] [Related]
12. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
Cutler NR; Sramek JJ
Alzheimer Dis Assoc Disord; 1995; 9(3):139-45. PubMed ID: 8534412
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate.
Hardiman S; Miller K; Murphy M
Acta Neurol Scand Suppl; 1993; 149():46-52. PubMed ID: 8128839
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
[TBL] [Abstract][Full Text] [Related]
15. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
16. Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.
Goa KL; Fitton A
CNS Drugs; 1994 Mar; 1(3):232-40. PubMed ID: 27520522
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
Pomara N; Deptula D; Singh R
Psychopharmacol Bull; 1991; 27(3):301-7. PubMed ID: 1775603
[TBL] [Abstract][Full Text] [Related]
18. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
19. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.
Ebmeier KP; Hunter R; Curran SM; Dougal NJ; Murray CL; Wyper DJ; Patterson J; Hanson MT; Siegfried K; Goodwin GM
Psychopharmacology (Berl); 1992; 108(1-2):103-9. PubMed ID: 1410128
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
Homma A; Atarashi H; Kubota N; Nakai K; Takase T
J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
